BOULDER, Colo.--(BUSINESS WIRE)--Crestone, Inc. (“Crestone”) today announced positive topline results from the Phase 2 clinical trial evaluating CRS3123 in patients with Clostridioides difficile ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback